Incidence and predictors of relapse during continuation treatment of major depression with SSRI, interpersonal psychotherapy, or their combination

Depression and Anxiety

Volumn 28, Issue 11, 2011, Pages 955-962

  Rucci, Paola ^a   Frank, Ellen ^b   Calugi, Simona ^c   Miniati, Mario ^c   Benvenuti, Antonella ^c   Wallace, Meredith ^b   Fagiolini, Andrea ^d   Maggi, Luca ^c   Kupfer, David J ^b   Cassano, Giovanni B ^d  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF PISA   (Italy)

^d UNIVERSITY OF SIENA   (Italy)

Author keywords

combined treatment; continuation phase; interpersonal psychotherapy; major depression; pharmacotherapy; predictors; relapse; remission; residual symptoms

Indexed keywords

ESCITALOPRAM;

ADULT; AGE; AGED; AGING; ARTICLE; DEMOGRAPHY; DISEASE SEVERITY; FEMALE; HUMAN; INCIDENCE; INTERPERSONAL PSYCHOTHERAPY; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROBABILITY; PSYCHOTHERAPY; RELAPSE; TREATMENT OUTCOME;

ACUTE DISEASE; ADOLESCENT; ADULT; AGED; CITALOPRAM; COMBINED MODALITY THERAPY; DEPRESSIVE DISORDER, MAJOR; FEMALE; HUMANS; INCIDENCE; LOGISTIC MODELS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PSYCHIATRIC STATUS RATING SCALES; PSYCHOTHERAPY; RECURRENCE; RISK FACTORS; SEROTONIN UPTAKE INHIBITORS; SEVERITY OF ILLNESS INDEX; YOUNG ADULT;

EID: 81255178336     PISSN: 10914269     EISSN: 15206394     Source Type: Journal    
DOI: 10.1002/da.20894     Document Type: Article

References (47)

1. Perlis RH, Nierenberg AA, Alpert JE, et al. Effects of adding cognitive therapy to fluoxetine dose increase on risk of relapse and residual depressive symptoms in continuation treatment of major depressive disorder. J Clin Psychopharmacol 2002; 22: 474-480.
2. Fawcett J,. Antidepressants: partial response in chronic depression. Br J Psychiatry 1994; 26: 37-41. (Pubitemid 24358527)
3. Bothwell R, Scott J,. The influence of cognitive variables on recovery in depressed inpatients. J Affect Disord 1997; 43: 207-212. (Pubitemid 27242467)
4. Thase ME, Simons AD, McGeary J, et al. Relapse after cognitive behavior therapy of depression: potential implications for longer courses of treatment. Am J Psychiatry 1992; 149: 1046-1052.
5. Judd LL, Akiskal HS, Maser JD, et al. Major depressive disorder: a prospective study of residual subthreshold depressive symptoms as predictor of rapid relapse. J Affect Disord 1998; 50: 97-108. (Pubitemid 28551779)
6. Fava GA,. Subclinical symptoms in mood disorders: pathophysiological and therapeutic implications. Psychol Med 1999; 29: 47-61. (Pubitemid 29034522)
7. Nierenberg AA, Keefe BR, Leslie VC, et al. Residual symptoms in depressed patients who respond acutely to fluoxetine. J Clin Psychiatry 1999; 60: 221-225. (Pubitemid 29193918)
8. Frank E, Prien RF, Jarrett RB, et al. Conceptualization and rationale for consensus definitions of terms in major depressive disorder. Remission, recovery, relapse, and recurrence. Arch Gen Psychiatry 1991; 48: 851-855.
9. Nierenberg AA, Petersen TJ, Alpert JE,. Prevention of relapse and recurrence in depression: the role of long-term pharmacotherapy and psychotherapy. J Clin Psychiatry 2003; 64: 13-17. (Pubitemid 37464492)
10. Hollon SD, Ponniah K,. A review of empirically supported psychological therapies for mood disorders in adults. Depress Anxiety 2010; 27: 891-932.
11. Garnock-Jones KP, McCormack PL,. Escitalopram: a review of its use in the management of major depressive disorder in adults. CNS Drugs 2010; 24: 769-796.
12. McGrath PJ, Stewart JW, Quitkin FM, et al. Predictors of relapse in a prospective study of fluoxetine treatment of major depression. Am J Psychiatry 2006; 163: 1542-1548. (Pubitemid 44465753)
13. Kaymaz N, van Os J, Loonen AJ, Nolen WA,. Evidence that patients with single versus recurrent depressive episodes are differentially sensitive to treatment discontinuation: a meta-analysis of placebo-controlled randomized trials. J Clin Psychiatry 2008; 69: 1423-1436.
14. Rapaport MH, Bose A, Zheng H,. Escitalopram continuation treatment prevents relapse of depressive episodes. J Clin Psychiatry 2004; 65: 44-49.
15. Hollon SD, Thase ME, Markowitz JC,. Treatment and prevention of depression. Psychol Sci 2002; 3: 39-77.
16. Oestergaard S, Møldrup C,. Optimal duration of combined psychotherapy and pharmacotherapy for patients with moderate and severe depression: a meta-analysis. J Affect Disord 2011; 131: 24-36.
17. Vittengl JR, Clark LA, Dunn TW, Jarrett RB,. Reducing relapse and recurrence in unipolar depression: a comparative meta-analysis of cognitive-behavioral therapy's effects. J Consult Clin Psychol 2007; 75: 475-488. (Pubitemid 47444751)
18. Driessen E, Hollon SD,. Cognitive behavioral therapy for mood disorders: efficacy, moderators and mediators. Psychiatr Clin North Am 2010; 33: 537-555.
19. Klerman GL, Weissman MM, Rounsaville BJ, Chevron ES,. Interpersonal Psychotherapy of Depression. New York: Basic Books; 1984.
20. Weissman MM, Markowitz JC, Klerman GL,. Comprehensive Guide to Interpersonal Psychotherapy. New York: Basic Books; 2000.
21. Frank E, Kupfer DJ, Perel JM, et al. Three-year outcomes for maintenance therapies in recurrent depression. Arch Gen Psychiatry 1990; 47: 1093-1099.
22. Kupfer DJ, Frank E, Perel JM, et al. Five-year outcome for maintenance therapies in recurrent depression. Arch Gen Psychiatry 1992; 49: 769-773.
23. Reynolds 3rd CF, Miller MD, Pasternak RE, et al. Treatment of bereavement-related major depressive episodes in later life: a controlled study of acute and continuation treatment with nortriptyline and interpersonal psychotherapy. Am J Psychiatry 1999; 156: 202-208. (Pubitemid 29077110)
24. Reynolds 3rd CF, Dew MA, Pollock BG, et al. Maintenance treatment of major depression in old age. N Engl J Med 2006; 354: 1130-1138.
25. Frank E, Kupfer DJ, Buysse DJ, et al. Randomized trial of weekly, twice-monthly, and monthly interpersonal psychotherapy as maintenance treatment for women with recurrent depression. Am J Psychiatry 2007; 164: 761-767. (Pubitemid 46808531)
26. Frank E, Cassano GB, Rucci P, et al. Predictors and moderators of time to remission of major depression with interpersonal psychotherapy and SSRI pharmacotherapy. Psychol Med 2011; 41: 151-162.
27. Cassano GB, Michelini S, Shear MK, et al. The panic-agoraphobic spectrum: a descriptive approach to the assessment and treatment of subtle symptoms. Am J Psychiatry 1997; 154: 27-38. (Pubitemid 27225244)
28. Fagiolini A, Dell'Osso L, Pini S, et al. Validity and reliability of a new instrument for assessing mood symptomatology: the Structured Clinical Interview for Mood Spectrum (SCI-MOODS). Int J Methods Psychiatr Res 1999; 8: 71-82.
29. Frank E, Cassano GB, Shear MK, et al. The spectrum model: a more coherent approach to the complexity of psychiatric symptomatology. CNS Spectrum 1998; 4: 23-34. (Pubitemid 29122693)
30. Dell'Osso L, Armani A, Rucci P, et al. Measuring mood spectrum: comparison of interview (SCI-MOODS) and self-report (MOODS-SR) instruments. Compr Psychiatry 2002; 43: 69-73. (Pubitemid 34056279)
31. Shear MK, Frank E, Rucci P, et al. Panic-agoraphobic spectrum: reliability and validity of assessment instruments. J Psychiatr Res 2001; 35: 59-66. (Pubitemid 32233171)
32. Dell'Osso L, Rucci P, Cassano GB, et al. Measuring social anxiety and obsessive-compulsive spectra: comparison of interviews and self-report instruments. Compr Psychiatry 2002; 43: 81-87. (Pubitemid 34205448)
33. Cassano GB, Benvenuti A, Miniati M, et al. The factor structure of lifetime depressive spectrum in patients with unipolar depression. J Affect Disord 2009; 115: 87-99.
34. Cassano GB, Mula M, Rucci P, et al. The structure of lifetime manic-hypomanic spectrum. J Affect Disord 2009; 112: 59-70.
35. Rucci P, Miniati M, Oppo A, et al. The structure of lifetime panic-agoraphobic spectrum. J Psychiatr Res 2009; 43: 366-379.
36. Miniati M, Rucci P, Frank E, et al. Sensitivity to change and predictive validity of the MOODS-SR questionnaire, last-month version. Psychother Psychosom 2009; 78: 116-124.
37. Benvenuti A, Rucci P, Calugi S, et al. Relationship of residual mood and panic-agoraphobic spectrum phenomenology to quality of life and functional impairment in patients with major depression. Int Clin Psychopharmacol 2010; 25: 68-74.
38. Rush AJ, Trivedi MH, Wisniewski SR, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry 2006; 163: 1905-1917. (Pubitemid 44807782)
39. Rapaport MH, Bose A, Zheng H,. Escitalopram continuation treatment prevents relapse of depressive episodes. J Clin Psychiatry 2004; 65: 44-49.
40. Kennedy SH, Giacobbe P,. Treatment resistant depression-advances in somatic therapies. Ann Clin Psychiatry 2007; 19: 279-287. (Pubitemid 350208805)
41. Mendlewicz J,. Towards achieving remission in the treatment of depression. Dialogues Clin Neurosci 2008; 10: 371-375.
42. Bech P, Lönn SL, Overø KF,. Relapse prevention and residual symptoms: a closer analysis of placebo-controlled continuation studies with escitalopram in major depressive disorder, generalized anxiety disorder, social anxiety disorder, and obsessive-compulsive disorder. J Clin Psychiatry 2010; 71: 121-129.
43. Yang H, Chuzi S, Sinicropi-Yao L, et al. Type of residual symptom and risk of relapse during the continuation/maintenance phase treatment of major depressive disorder with the selective serotonin reuptake inhibitor fluoxetine. Eur Arch Psychiatry Clin Neurosci 2010; 260: 145-150.
44. Paykel ES,. Cognitive therapy in relapse prevention in depression. Int J Neuropsychopharmacol 2007; 10: 131-136. (Pubitemid 46122761)
45. Petersen TJ,. Enhancing the efficacy of antidepressants with psychotherapy. J Psychopharmacol 2006; 20: 19-28. (Pubitemid 44605929)
46. Perlis RH, Nierenberg AA, Alpert JE, et al. Effects of adding cognitive therapy to fluoxetine dose increase on risk of relapse and residual depressive symptoms in continuation treatment of major depressive disorder. J Clin Psychopharmacol 2002; 22: 474-480.
47. Iovieno N, van Nieuwenhuizen A, Clain A, et al. Residual symptoms after remission of major depressive disorder with fluoxetine and risk of relapse. Depress Anxiety 2011; 28: 137-144.